The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 55
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_DerivativeFinancialLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash inflow from issuing shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ProceedsFromIssuingShares
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2024-01-01
-Paragraph 114
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2024-01-01
-Paragraph 113
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of additional proceeds receivable upon exercise of warrants.

+ References

No definition available.

+ Details

Name:	iva_AdditionalProceedsReceivableUponExerciseOfWarrants
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate amount to be received by the company, either in exchange for new shares or warrants of the Company.

+ References

No definition available.

+ Details

Name:	iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Subscription price per share or per unit of warrants or rights outstanding.

+ References

No definition available.

+ Details

Name:	iva_ClassOfWarrantOrRightSubscriptionPrice
Namespace Prefix:	iva_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

No definition available.

+ Details

Name:	iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
Namespace Prefix:	iva_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details

Name:	iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix:	iva_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

No definition available.

+ Details

Name:	iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	iva_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.

+ References

No definition available.

+ Details

Name:	iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems
Namespace Prefix:	iva_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).

+ References

No definition available.

+ Details

Name:	iva_IfrsProceedsFromIssuanceOfWarrants
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	iva_IfrsSharesIssuedPricePerShare
Namespace Prefix:	iva_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of milestone payment receivable in license and collaboration agreements.

+ References

No definition available.

+ Details

Name:	iva_LicenseAndCollaborationAgreementMilestonePaymentReceivableUponAchievementOfCertainMilestone
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Value of credit note recognized during the period under license and collaborative arrangement.

+ References

No definition available.

+ Details

Name:	iva_LicenseAndCollaborationArrangementCreditNoteRecognized
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Gross amount of revenue from milestone payments recognized during the period under license and collaborative arrangement.

+ References

No definition available.

+ Details

Name:	iva_LicenseAndCollaborativeArrangementGrossRevenueFromMilestonePaymentRecognized
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Net proceeds from issuance of shares and warrants.

+ References

No definition available.

+ Details

Name:	iva_NetProceedsFromIssuanceOfSharesAndWarrants
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the number of days Phase 1 trial of lanifibranor.

+ References

No definition available.

+ Details

Name:	iva_NumberOfDaysInPhase1TrialOfLanifibranor
Namespace Prefix:	iva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the number of participants Phase 1 trial of lanifibranor.

+ References

No definition available.

+ Details

Name:	iva_NumberOfParticipantsInPhase1TrialOfLanifibranor
Namespace Prefix:	iva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the number of subjects randomized.

+ References

No definition available.

+ Details

Name:	iva_NumberOfSubjectsRandomized
Namespace Prefix:	iva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of warrants issued

+ References

No definition available.

+ Details

Name:	iva_NumberOfWarrantsIssued
Namespace Prefix:	iva_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Proceeds from issuance of shares and warrants.

+ References

No definition available.

+ Details

Name:	iva_ProceedsFromIssuanceOfSharesAndWarrants
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount paid on licensing arrangements.

+ References

No definition available.

+ Details

Name:	iva_ProceedsFromLicensingArrangements
Namespace Prefix:	iva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of reduction in workforce as per agreement under the restructuring plan.

+ References

No definition available.

+ Details

Name:	iva_RestructuringAndRelatedCostWorkforceReductionPercentage
Namespace Prefix:	iva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The number of shares issued during the period.

+ References

No definition available.

+ Details

Name:	iva_StockIssuedDuringPeriodShares
Namespace Prefix:	iva_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsSaleOfStockAxis=iva_FinancingArrangementInThreeTranches2024TrancheIPhaseIiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsSaleOfStockAxis=iva_FinancingArrangementInThreeTranches2024TrancheIiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfFinancialInstrumentsAxis=iva_T2NewSharesCallOptionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfFinancialInstrumentsAxis=iva_T2BsaCallOptionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsClassOfWarrantOrRightAxis=iva_T1BsaWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsSaleOfStockAxis=iva_FinancingArrangementInThreeTranches2024TrancheIPhaseIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsClassOfWarrantOrRightAxis=iva_T1BisBsaWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsClassOfWarrantOrRightAxis=iva_T2BsaPrefundedWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsClassOfWarrantOrRightAxis=iva_T3BsasWarrantsAttachedToT2NewSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsClassOfWarrantOrRightAxis=iva_T3BsasWarrantsAttachedToT2BsaWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsClassOfWarrantOrRightAxis=iva_PreFundedWarrantsBsasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=iva_T1NewShareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=iva_T1BisSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=iva_T2NewShareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=iva_T2NewShareAndT3BsasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsSaleOfStockAxis=iva_FinancingArrangementInThreeTranches2024Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsClassOfWarrantOrRightAxis=iva_T3BsaWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsClassOfWarrantOrRightAxis=iva_AbsaWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_ReceiptOfPaymentsUnderLicensingArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAgreementWithHepalysMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_GeographicalAreasAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Phase3Nativ3ClinicalTrialOfLanifibranorInPatientsWithMashAndAdvancedFibrosisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Company information - (Details) € / shares in Units, € in Thousands, $ in Millions								1 Months Ended		6 Months Ended
	Jul. 07, 2025 EUR (€)	Jul. 07, 2025 USD ($)	May 09, 2025 EUR (€)	May 07, 2025 EUR (€) € / shares shares	May 02, 2025 € / shares shares	Dec. 19, 2024 EUR (€) € / shares shares	Oct. 17, 2024 EUR (€) € / shares shares	May 31, 2025 EUR (€)	May 31, 2025 USD ($)	Jun. 30, 2025 EUR (€) item D shares	Jun. 30, 2025 USD ($) shares	Jun. 30, 2024 EUR (€)	May 07, 2025 USD ($) shares	Feb. 28, 2025 item	Dec. 31, 2024 EUR (€) shares	Dec. 11, 2024 € / shares shares	Oct. 14, 2024 EUR (€)
Collaborative Arrangements
Proceeds from issuance of shares										€ 57,370		€ 6
Issue of prefunded warrants										58,206
Derivative financial liabilities										42,251					€ 97,715
Revenue										€ 4,454		€ 41
Forecast
Collaborative Arrangements
Percentage of reduction in workforce														50.00%
Tranche I, phase II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Proceeds from issuance of shares and warrants						€ 21,400
Net proceeds from issuance of shares and warrants						€ 20,100
Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Proceeds from issuance of shares and warrants				€ 115,600
Net proceeds from issuance of shares and warrants				108,000
T2 New Shares Call options \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Derivative financial liabilities				78,200
T2 BSA Call options \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Derivative financial liabilities				€ 79,900
T1 BSA Warrants [Member] \| Tranche I, phase I, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Proceeds from issuance of shares and warrants							€ 94,100
Net proceeds from issuance of shares and warrants							€ 86,600
Exercise price of warrant \| € / shares							€ 0.01
Number of warrants issued \| shares							35,399,481
Subscription price per warrant \| € / shares							€ 1.34
Number of shares callable by warrants \| shares							35,399,481
T1 bis BSA Warrants \| Tranche I, phase II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Exercise price of warrant \| € / shares						€ 0.01
Number of warrants issued \| shares						8,053,847
Number of shares callable by warrants \| shares						8,053,847
T2 BSA Prefunded Warrants
Collaborative Arrangements
Price per share \| € / shares					€ 1.35
Subscription price per warrant \| € / shares					€ 1.34
Number of shares callable by warrants \| shares					43,437,036
T2 BSA Prefunded Warrants \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Number of shares per warrant \| shares				1	1								1		1	1
Price per share \| € / shares				€ 1.35
Number of warrants issued \| shares				43,437,036	43,437,036					43,437,036	43,437,036
Subscription price per warrant \| € / shares				€ 1.34
Issue of prefunded warrants				€ 58,200
Number of shares callable by warrants \| shares				43,437,036									43,437,036
T3 BSAs Warrants Attached To T2 New Shares \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Exercise price of warrant \| € / shares				€ 1.5	€ 1.5
Number of shares callable by warrants \| shares				38,239,990	38,239,990								38,239,990
T3 BSAs Warrants Attached To T2 BSA Warrants
Collaborative Arrangements
Exercise price of warrant \| € / shares					€ 1.5
Number of shares callable by warrants \| shares					39,093,329
T3 BSAs Warrants Attached To T2 BSA Warrants \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Exercise price of warrant \| € / shares				€ 1.5
Number of shares callable by warrants \| shares				39,093,329									39,093,329
T2 and T3 BSAs \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Subscription price per warrant \| € / shares				€ 1.34
Issue of prefunded warrants				€ 58,200
T1 New Share \| Tranche I, phase I, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Number of shares issued during the period \| shares							34,600,507
Price per share \| € / shares							€ 1.35
T1 BIS Shares [Member] \| Tranche I, phase II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Number of shares issued during the period \| shares						7,872,064
Price per share \| € / shares						€ 1.35
T2 New Share \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Number of shares issued during the period \| shares				42,488,883	42,488,883					42,488,883	42,488,883
Price per share \| € / shares				€ 1.35
Proceeds from issuance of shares				€ 57,400
T2 New Share \| T3 BSAs Warrants Attached To T2 New Shares \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Number of shares per warrant \| shares				1									1
ABSAs \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Price per share \| € / shares				€ 1.35	€ 1.35
Maximum \| 2024 Financing arrangement in three tranches
Collaborative Arrangements
Structured Financing amount																	€ 348,000
Maximum \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Structured Financing amount																	€ 116,000
Maximum \| T2 BSA Prefunded Warrants \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Exercise price of warrant \| € / shares																€ 1.35
Maximum \| T3 BSA warrants \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Additional proceeds receivable upon exercise of warrants				€ 116,000
Maximum \| T3 BSAs Warrants Attached To T2 New Shares \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Additional proceeds receivable upon exercise of warrants				57,400
Maximum \| T3 BSAs Warrants Attached To T2 BSA Warrants \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Additional proceeds receivable upon exercise of warrants				€ 58,600
Maximum \| T2 and T3 BSAs \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Number of shares callable by warrants \| shares				120,800,000									120,800,000
Maximum \| T2 New Share \| ABSA warrants \| Tranche II, 2024 Financing arrangement in three tranches
Collaborative Arrangements
Exercise price of warrant \| € / shares																€ 1.35
Licensing and collaboration agreement with CTTQ
Collaborative Arrangements
Milestone payment receivable \| $													$ 10.0
Revenue										€ 4,400
Gross amount of revenue										8,900	$ 10.0
License and collaboration arrangement, credit note recognized			€ 4,400					€ 4,400	$ 5.0	€ 4,300
Licensing and collaboration agreement with CTTQ \| Receipt of payments under Licensing arrangements
Collaborative Arrangements
Amount received on licensing arrangements	€ 8,500	$ 9.5
Licensing agreement with Hepalys \| JAPAN
Collaborative Arrangements
Number of Participants in Phase 1 Trial of Lanifibranor \| item										32
Number of days in Phase 1 trial of Lanifibranor \| D										14
Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Collaborative Arrangements
Number of patients randomized \| item														1,200